Phase 2 N=8 Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea
Morphea
Primary: Number of Participants Who Had a Reduction in Dermal Thickness of Sentinel Plaque — 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=142 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
N/A N=45 Scleroderma ARFI Imaging of the Skin
Scleroderma
Primary: Mean Skin Stiffness — 2.68; 2.07; 2.23; 2.27 meters per second — p=0.005
Phase 2 N=20 Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Systemic Sclerosis
Primary: Change in Modified Rodnan Skin Score (MRSS) — -10; -3.0 units on a scale
Phase 2 N=12 Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
Phase 3 N=6 High Dose Cyclophosphamide for Treatment of Scleroderma
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Phase 3 N=75 Scleroderma: Cyclophosphamide or Transplantation
Scleroderma, Systemic · Sclerosis · Autoimmune Disease
Primary: Global Rank Composite Score (GRCS) (Month 54, ITT) — 17.0; -6.0 Sum of subject-pair comparison scores — p=0.013
N/A N=7 Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement
Scleroderma, Systemic
Primary: Mean Change From Baseline in Forced Vital Capacity (FVC) — 0.1786 Liters — p=0.026
Phase 2 N=19 IL1-TRAP, Rilonacept, in Systemic Sclerosis
Scleroderma · Systemic Sclerosis · Diffuse Scleroderma
Primary: Change in 2- Gene Biomarker — -2.67; 0.42 2- gene biomarkers score
Phase 3 N=158 Scleroderma Lung Disease
Lung Diseases · Pulmonary Fibrosis · Systemic Scleroderma
Primary: Forced Vital Capacity — 66.6; 65.6 % of predicted
Phase 2 N=10 A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
Scleroderma, Diffuse · Scleroderma, Systemic
Primary: Change in Modified Rodnan Skin Score — -8.6; -2.3 MRSS score
Phase 2 N=51 Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
Scleroderma, Systemic · Interstitial Lung Disease
Primary: Percent Predicted Forced Vital Capacity (FVC-%) — 2.24; 2.09 percent predicted — p=0.9326
Phase 2 N=8 Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
Epidermolysis Bullosa Simplex · Epidermolysis Bullosa Simplex Kobner · Weber-Cockayne Syndrome
Primary: Foot Health Status Questionnaire, Foot Function Domain Score — 61.7; 49.3; 60.2; 56.3 score on a scale
Phase 2 N=12 Study of EB-001 in Facial Scar Reduction
Mohs Surgery
Primary: Assessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best)) — 0; 50 Percentage reporting improvement
N/A N=15 Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Systemic Sclerosis · Scleroderma
Primary: The Benefit That an Antifibrotic Agent and Ambrisentan Combination Have on the Cutaneous Involvement of Patients With Early Diffuse Systemic Sclerosis by Utilizing the…
Phase 2 N=19 Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
SYSTEMIC SCLERODERMA
Primary: Time to Treatment Failure — 0; 8 participants
Phase 2 N=88 A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
Primary: Proportion of Participants With at Least One Adverse Events (AEs) or Serious AEs (SAEs) in 1 Year — 35; 40 Participants
Phase 2 N=21 Scleroderma Treatment With Autologous Transplant (STAT) Study
Systemic Scleroderma
Primary: EFS of Patients Undergoing Transplant — 15 participants
N/A N=12 The CO2RE® System for Vulvar Lichen Sclerosus
Vulvar Lichen Sclerosus
Primary: Average Scores for VLS Clinical Signs Present At Baseline, 3, 6 and 12 Months After the Last Treatment as Assessed by the Investigators — 1.85; 0.65; 0.65; 0.73 score on…